[go: up one dir, main page]

ATE529409T1 - Verfahren zur herstellung von kristallinen aripiprazolformen - Google Patents

Verfahren zur herstellung von kristallinen aripiprazolformen

Info

Publication number
ATE529409T1
ATE529409T1 AT04815093T AT04815093T ATE529409T1 AT E529409 T1 ATE529409 T1 AT E529409T1 AT 04815093 T AT04815093 T AT 04815093T AT 04815093 T AT04815093 T AT 04815093T AT E529409 T1 ATE529409 T1 AT E529409T1
Authority
AT
Austria
Prior art keywords
crystalline forms
aripiprazole
producing crystalline
aripiprazole crystalline
producing
Prior art date
Application number
AT04815093T
Other languages
English (en)
Inventor
Judith Aronhime
Ben-Zion Dolitzky
Eran Luvchick
Jean Hildesheim
Hagit Eisen-Nevo
Reuven Izsak
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34705304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE529409(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE529409T1 publication Critical patent/ATE529409T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT04815093T 2003-12-16 2004-12-16 Verfahren zur herstellung von kristallinen aripiprazolformen ATE529409T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53029703P 2003-12-16 2003-12-16
US53383103P 2003-12-30 2003-12-30
US61840404P 2004-10-13 2004-10-13
US61896004P 2004-10-14 2004-10-14
PCT/US2004/042976 WO2005058835A2 (en) 2003-12-16 2004-12-16 Methods of preparing aripiprazole crystalline forms

Publications (1)

Publication Number Publication Date
ATE529409T1 true ATE529409T1 (de) 2011-11-15

Family

ID=34705304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04815093T ATE529409T1 (de) 2003-12-16 2004-12-16 Verfahren zur herstellung von kristallinen aripiprazolformen

Country Status (11)

Country Link
US (2) US7504504B2 (de)
EP (1) EP1613598B1 (de)
JP (2) JP5546717B2 (de)
AT (1) ATE529409T1 (de)
CA (1) CA2550726A1 (de)
ES (1) ES2374922T3 (de)
IL (1) IL175512A (de)
PL (1) PL1613598T3 (de)
PT (1) PT1613598E (de)
TW (1) TW200529850A (de)
WO (1) WO2005058835A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009990A1 (en) * 2003-07-25 2005-02-03 Hetero Drugs Limited Aripiprazole crystalline forms
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
EP1732610A2 (de) 2004-03-26 2006-12-20 Baylor University Gezielte inhibitoren der serotonin-wiederaufname
EP1797039A1 (de) 2004-09-13 2007-06-20 Matrix Laboratories Ltd Verfahren zur herstellung von polymorphen, solvaten von aripiprazol unter verwendung von aripiprazolsäuresalzen
EP1812396A1 (de) 2004-11-18 2007-08-01 Synthon B.V. Kristalline aripiprazolsolvate
WO2006053781A1 (en) * 2004-11-18 2006-05-26 Synthon B.V. Process of making crystalline aripiprazole
EP1686117A1 (de) * 2005-01-27 2006-08-02 Sandoz AG Polymorph und Solvate von Aripiprazol
WO2006097343A1 (en) † 2005-03-17 2006-09-21 Synthon B.V. Process of making crystalline type ii aripiprazole
ES2526415T3 (es) 2005-03-17 2015-01-12 Synthon B.V. Comprimidos farmacéuticos de aripiprazol cristalino de tipo II
EP1879865A1 (de) * 2005-04-15 2008-01-23 Medichem S.A. Synthesen und herstellungen von polymorphen aus kristallinem aripiprazol
WO2007041414A1 (en) 2005-09-29 2007-04-12 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form ii
JP2008537540A (ja) * 2005-12-22 2008-09-18 テバ ファーマシューティカル インダストリーズ リミティド アリピプラゾールの粒径を小さくする方法
US20070154545A1 (en) * 2006-01-05 2007-07-05 Julia Hrakovsky Dry formulations of aripiprazole
EP2036545A1 (de) * 2006-01-05 2009-03-18 Teva Pharmaceutical Industries Ltd. Aripiprazol-Tabletten
TWI394753B (zh) * 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
EP1880714A1 (de) 2006-07-20 2008-01-23 Helm AG Amorphes Aripiprazol und Verfahren zu dessen Herstellung
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
WO2008020453A2 (en) * 2006-08-17 2008-02-21 Unichem Laboratories Limited A process for the preparation of a novel crystalline polymorph of aripiprazole
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
ES2401603T3 (es) * 2006-10-24 2013-04-23 Cambrex Charles City, Inc. Procedimiento para preparar aripiprazol anhidro de tipo l
ES2353444T3 (es) 2008-01-23 2011-03-02 Helm Ag Aripiprazol amorfo y procedimiento para su preparación.
EP2238976B1 (de) 2009-04-03 2012-06-27 Hexal AG Oraler Film mit 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-chinolin-2-on-Base oder Salze oder Hydrate davon
CN101948426A (zh) * 2010-09-13 2011-01-19 浙江华海药业股份有限公司 一种制备阿立哌唑晶型b的新方法
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
ES2675913T3 (es) 2010-10-28 2018-07-13 Aequus Pharmaceuticals Inc. Composiciones de aripiprazol y métodos para su administración transdérmica
WO2012077134A1 (en) * 2010-12-07 2012-06-14 Ind-Swift Laboratories Limted Process for preparing aripiprazole polymorphs
KR101340214B1 (ko) * 2011-03-31 2013-12-10 주식회사 대웅제약 무수 아리피프라졸 ⅱ형 결정의 제조방법
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
KR101372840B1 (ko) * 2012-08-02 2014-03-12 주식회사 에스텍파마 무수 아리피프라졸 결정의 제조방법
WO2015067313A1 (en) 2013-11-07 2015-05-14 Synthon B.V. Orodispersible pharmaceutical compositions comprising aripiprazole
CN105916502A (zh) 2013-11-15 2016-08-31 阿克比治疗有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的固体形式，其组合物和用途
CN106474058B (zh) 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
TWI665194B (zh) * 2016-02-19 2019-07-11 諾瑞特國際藥業股份有限公司 阿立哌唑的新晶型

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
US6221153B1 (en) * 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
AU2001250892A1 (en) 2000-03-20 2001-10-03 Teva Pharmaceutical Industries Ltd. Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and n-(4-methoxyphenyl)-3-chloropropionamide
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ITMI20021209A1 (it) 2002-06-04 2003-12-04 Chemi Spa Processo di preparazione di azitromicina ad elevata purezza
WO2004017897A2 (en) * 2002-08-20 2004-03-04 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
BRPI0305500B1 (pt) * 2003-01-09 2018-01-23 Otsuka Pharmaceutical Co., Ltd. Processo para preparar aripiprazol
US7491726B2 (en) * 2003-03-21 2009-02-17 Hetero Drugs Limited Crystalline forms of aripiprazole
EP1618103A2 (de) * 2003-04-25 2006-01-25 Cadila Healthcare Ltd. Polymorphe von aripiprazol
CA2428237C (en) 2003-05-08 2010-07-20 Delmar Chemicals Inc. Process for the preparation of carbostyril derivatives
WO2005009990A1 (en) * 2003-07-25 2005-02-03 Hetero Drugs Limited Aripiprazole crystalline forms
US7166418B2 (en) * 2003-09-03 2007-01-23 Matsushita Electric Industrial Co., Ltd. Sulfonamide compound, polymer compound, resist material and pattern formation method
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
US20050277650A1 (en) * 2004-04-20 2005-12-15 Sundaram Venkataraman Process for preparing aripirazole hydrate
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2006012237A2 (en) 2004-06-25 2006-02-02 Shanghai Institute Of Pharmaceutical Industry Aripiprazole crystaline forms and associated methods
EP1797039A1 (de) 2004-09-13 2007-06-20 Matrix Laboratories Ltd Verfahren zur herstellung von polymorphen, solvaten von aripiprazol unter verwendung von aripiprazolsäuresalzen
DE102005048695A1 (de) * 2004-10-12 2006-05-18 Chemagis Ltd. Verfahren zur Herstellung und Reinigung von Carbostyrilverbindungen wie beispielsweise Aripiprazol und 7-(4-Halobutoxy)-3,4-dihydro-2(1H)-quinolinonen
DE102005048694A1 (de) * 2004-10-12 2006-05-18 Chemagis Ltd. Verbesserte Verfahren zur Herstellung von 7-Hydroxy-3,4-dihydro-2(1H)-quinolinon und dessen Verwendung in der Herstellung von Aripiprazol
EP1812396A1 (de) * 2004-11-18 2007-08-01 Synthon B.V. Kristalline aripiprazolsolvate
WO2006053781A1 (en) * 2004-11-18 2006-05-26 Synthon B.V. Process of making crystalline aripiprazole
EP1686117A1 (de) * 2005-01-27 2006-08-02 Sandoz AG Polymorph und Solvate von Aripiprazol
EP2279727A3 (de) * 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoteilchenförmige Aripiprazolformulierungen
JP2008537540A (ja) * 2005-12-22 2008-09-18 テバ ファーマシューティカル インダストリーズ リミティド アリピプラゾールの粒径を小さくする方法
US20070213535A1 (en) * 2006-03-07 2007-09-13 Chemagis Ltd. Process for the manufacture of aripiprazole by using purified carbostyril compounds such as 7-(4-halobutoxy)-3,4-dihydro-2(1H)-quinolinones
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
WO2007113846A1 (en) * 2006-04-03 2007-10-11 Alembic Limited A process for the preparation of aripiprazole
US20070238876A1 (en) * 2006-04-10 2007-10-11 Neera Tewari Process for the preparation of aripiprazole
EP1880714A1 (de) * 2006-07-20 2008-01-23 Helm AG Amorphes Aripiprazol und Verfahren zu dessen Herstellung

Also Published As

Publication number Publication date
JP2007517783A (ja) 2007-07-05
EP1613598A2 (de) 2006-01-11
JP2013237682A (ja) 2013-11-28
IL175512A0 (en) 2006-09-05
EP1613598B1 (de) 2011-10-19
US7504504B2 (en) 2009-03-17
PT1613598E (pt) 2012-01-13
TW200529850A (en) 2005-09-16
US20050203299A1 (en) 2005-09-15
ES2374922T3 (es) 2012-02-23
IL175512A (en) 2014-11-30
US20090156813A1 (en) 2009-06-18
JP5546717B2 (ja) 2014-07-09
WO2005058835A2 (en) 2005-06-30
PL1613598T3 (pl) 2012-03-30
WO2005058835A3 (en) 2005-08-11
CA2550726A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
ATE529409T1 (de) Verfahren zur herstellung von kristallinen aripiprazolformen
ATE425136T1 (de) Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
DE602004031895D1 (de) Verfahren zur Herstellung von Dichlorpropanol
DE60323192D1 (de) Verfahren zur Herstellung von Hydroxyalkylstärkederivaten
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
DE602004010234D1 (de) Verfahren zur herstellung von 4-aminodiphenylamin
ATE482966T1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
ATE308524T1 (de) Verfahren zur herstellung von aripiprazole
EP1809613A4 (de) Verfahren zur herstellung von 2,6-diarylpiperidinderivaten
DE50311721D1 (de) Verfahren zur Herstellung von Aryl-aminopropanolen
ATE424892T1 (de) Verfahren zur herstellung von derivaten des 4a,5, 9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
DE60210778D1 (de) Verfahren zur herstellung von 4-amino-2,5-bisheterocyclylchinazolinen
DE60322356D1 (de) Verfahren zur herstellung von 2-aminoindanderivaten
DE602005014280D1 (de) Verfahren zur herstellung von ä1,4,5ü-oxadiazepinderivaten
DE50211253D1 (de) Verfahren zur Herstellung von Makrokapseln
DE602004027840D1 (de) Verfahren zur herstellung von thiazolopyrimidinen
DE602004005239D1 (de) Verfahren zur herstellung von tubulininhibitoren
DE602004012912D1 (de) Verfahren zur Herstellung von Fluorhalogenethern
DE60301444T2 (de) Verfahren zur Herstellung von Polyalkylphenoxyaminoalkanen
DE60302979D1 (de) Verfahren zur Herstellung von Epsilon-Caprolactone
DE602004018447D1 (de) Verfahren zur Herstellung von Alkylbenzaldehyden
DE602004031727D1 (de) Neues verfahren und zwischenprodukte zur herstellung von 19-nor-steroiden
EP1720840A4 (de) Verfahren zur herstellung von 1,3-dioxolannukleosiden
DE602004025752D1 (de) Verfahren zur herstellung von 4,4,4-trifluorbutan-2-on
DE502004005103D1 (de) Verfahren zur Herstellung von Acyloxybenzolsulfonaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1613598

Country of ref document: EP